Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BNBX vs PACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BNBX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 3–5 Matrix Metrics)

BNBX Overall Winner 6-Pillar Tally: BNBX 4 – 1 PACB (1 Tie) Matrix Metrics: BNBX 3 – 5 PACB

As of Nov 16, 2026, BNB Plus Corp. (BNBX) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.88 (N/M Forward P/E, -333.0% operating margin).

  • Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. BNBX 37.7/100 SELL), BNBX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-636.4% vs. -333.0% operating margin) and revenue trajectory (+34.3% vs. +5.5% YoY).
  • Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BNBX vs PACB
BNBX US Equity Head-to-Head Winner
BNB Plus Corp.
Finance Services
$0.16
-56.75% 1D
Market Cap $2.7M
TTM Revenue $2.1M
Forward P/E N/M
Beta / 30D Vol 1.68β · 227% Vol
Unified Composite Score
37.7 / 100 SELL
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.6%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $0.39 · SMA50: $0.44
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.88
-4.34% 1D
Market Cap $615.1M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.24β · 110% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 15.0 Fund 36.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.4 · SMA20: $2.29 · SMA50: $2.02

6-Pillar Scorecard Institutional Category Breakdown (BNBX 4 – 1 PACB)

Columns: Metric · BNBX · PACB
1. Valuation Multiples BNBX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 1.27x N/M
EV / Revenue 0.8x 7.8x
2. Growth & Scale PACB
Revenue Growth (YoY) +34.3% +5.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.1M $161M
Market Cap $2.7M $615.1M
3. Profitability & Quality BNBX
Gross Margin 46.8% 27.7%
Operating Margin -636.4% -333.0%
Net Profit Margin 0.0% -81.3%
Return on Equity (ROE) -306.8% -929.3%
4. Balance Sheet & Cash Flow BNBX
Cash Generation (TTM) -$32M EBITDA -$150M
Cash Flow Margin N/A -93.2%
Net Cash / Leverage -$949,091 Net Debt (0.00x D/E) $649M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BNBX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 92.6% (47th %ile)
Put/Call OI Skew N/A 0.19x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Asset Management Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BNBX (3) vs PACB (5)
Institutional Metric BNBX PACB Criterion Row Edge
Market Capitalization
Scale
$2.7M $615.1M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+34.3% +5.5% Higher Growth BNBX
Operating Margin (TTM)
Profitability
-636.4% -333.0% Higher Margin PACB
Net Profit Margin
Profitability
0.0% -81.3% Higher Margin BNBX
Return on Equity (ROE)
Capital Efficiency
-306.8% -929.3% Higher ROE BNBX
52-Week Range Position
Momentum
0% ($0–$7) 34% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
1.68β · 227% Vol 2.24β · 110% Vol Lower Realized Risk PACB
Unified Institutional Score
Composite Signal
37.7 / 100 (SELL) 42.0 / 100 (HOLD) Higher Composite PACB
Trailing 12M Revenue (USD)
Operating Scale
$2.1M $161M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.8% 27.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.27x PEG · 0.8x EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M EBITDA (-$949,091 Net Debt (0.00x D/E)) -$150M ($649M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +76.16 pp
BNBX: -67.4% · PACB: +8.76%
3M Horizon PACB +83.09 pp
BNBX: -71.9% · PACB: +11.19%
6M Horizon PACB +62.98 pp
BNBX: -89.94% · PACB: -26.96%
1Y Horizon PACB +86.17 pp
BNBX: -94.76% · PACB: -8.59%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BNBX Revenue PACB Revenue BNBX Op. Margin PACB Op. Margin Margin Leader
FY2018 $0M $80M -298.4% -128.4% PACB
FY2019 $10M $90M -169.3% -110.6% PACB
FY2020 $0M $80M -649.0% -132.3% PACB
FY2021 $10M $130M -147.9% -161.2% BNBX
FY2022 $20M $130M -76.9% -239.4% BNBX
FY2023 $10M $200M -81.9% -166.8% BNBX
FY2024 $0M $150M -646.7% -308.0% PACB
FY2025 $0M $160M -750.9% -346.2% PACB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BNBX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BNBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 92.6%
IV Percentile 47th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BNBX Moat Profile Cyclical / Execution-Driven Positioning
Asset Management Operator
Competes within the Asset Management value chain with $2.7M market capitalization and -636.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $615.1M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BNBX vs PACB Key Questions & Quantitative Answers

As of Nov 16, 2026, BNB Plus Corp. (BNBX) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.88 (N/M Forward P/E, -333.0% operating margin). Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. BNBX 37.7/100 SELL), BNBX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-636.4% vs. -333.0% operating margin) and revenue trajectory (+34.3% vs. +5.5% YoY). Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: BNBX posts +34.3% YoY revenue growth and +0.0% YoY earnings growth on $2.1M TTM revenue (46.8% gross margin, -636.4% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BNBX cumulative revenue shifted +0.0% while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, BNBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.

BNBX screens cheaper on headline valuation multiples. BNBX trades at N/M Forward P/E, N/M Trailing P/E, 1.27x PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BNBX (-306.8% ROE) versus PACB (-929.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BNBX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 227% Vol realized risk). By comparison, PACB carries 92.6% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 110% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.